THE WOODLANDS, Texas, Nov. 8, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company, announces that Dr. Ira L. Goldknopf, Chief Scientific Officer, has been invited to present at Stanford University's seminar on the "Evolution of Cancer Therapy: From Pathways to Patients" on November 11, 2004. Dr. Goldknopf will discuss Power3 Medical's breakthroughs in developing proteomic-based diagnostic tests for the early detection of breast cancer and neurodegenerative diseases.
"Evolution of Cancer Therapy: From Pathways to Patients" was inspired by the desire to highlight how basic research on cancer diagnosis and treatment translates to the clinic, and to educate members of the research and medical community about how this is accomplished. Speakers at this event include: Stefanie Jeffrey, MD, Catherine Park, MD, Mark Pegram, MD, Lance Liotta, MD, PhD, Ira Goldknopf, PhD, David Benaron, MD, and Sam Gambhir, MD, PhD.
This year's symposium is focused on breast cancer as a particular system. According to Dr. Goldknopf, "The early detection of breast cancer is particularly important because of the high degree of genetic instability in this disease. Our preliminary data suggest that by analyzing certain protein biomarkers we have the potential to develop a more sensitive indication of breast cancer than mammography. The function of our breast cancer protein biomarkers suggests that they might also be key players in the first line of defense against genetic instability, suggesting that these identified proteins may play a very early role in the development of breast cancer."
Dr. Goldknopf's pioneering proteomic discovery, the first ubiquitin conjugate, Protein A24 (aka uH2A), was cited in the announcement for this year's Nobel Prize in Chemistry. Dr. Goldknopf and the scientific team at Power3 have developed a proteomic test using breast nipple aspirate fluid to generate a protein disease footprint, i.e., a panel of ubiquitin system and other proteins, that detects cancer initiation before the cancer is detectable by mammography.
The Company's NAF Test, for the detection, diagnosis, and monitoring of breast cancer, utilizes fluids from the breast called nipple aspirates to identify groups of breast cancer proteins. The initial clinical evaluation of this product proved remarkably effective and the Company is currently involved in a multi-site clinical validation trial at NYU Medical Center, Mercy Women's Center, and the Clinical Research Center of Houston, (OGA).
About Power3 Medical Products, Inc.
Power3 Medical Products, www.power3medical.com, is a biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.